It is a therapeutic equivalent generic version of NAMENDA (memantine HCl) tablets in the US market
Dr Reddy’s Laboratories has launched memantine hydrochloride tablets USP, 5 mg and 10 mg, a therapeutic equivalent generic version of NAMENDA (memantine HCl) tablets in the US market on July 12, 2015, approved by the United States Food and Drug Administration (US FDA).
The NAMENDA (memantine HCl) tablets brand had US sales of approximately $1.4 billion MAT for the most recent twelve months ending in May 2015 according to IMS Health*.
Dr Reddy’s Memantine hydrochloride tablets USP, 5 mg is available in bottle count size of 60 and the Memantine hydrochloride tablets USP, 10 mg are available in bottle count sizes of 60 and 500.
Comments are closed.